FXH
First Trust Health Care AlphaDEX Fund
First Trust Health Care AlphaDEX Fund seeks investment results that correspond to the StrataQuant Health Care AlphaDEX Index.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 872.3 M
ASSETS UNDER MGMT
62 bp
EXPENSES
Fund Basics
| Inception date | May 08, 2007 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ORGANON & CO. | 3.9 % |
| HUMANA INC | 2.9 % |
| ELEVANCE HEALTH INC | 2.8 % |
| MOLINA HEALTHCARE INC | 2.5 % |
| CIGNA CORPORATION | 2.3 % |
| GLOBUS MEDICAL INC - A | 2.3 % |
| INCYTE CORP | 2.2 % |
| SOLVENTUM CORP | 2.2 % |
| BIOGEN IDEC INC | 2.2 % |
| EXELIXIS INC | 2.2 % |
Constituent Breakdown
| Number of holdings | 77 |
| Herfindahl-Hirschman Index | 171 |
| Wgt avg mkt cap (mns) | $77,906 |
| Large cap (>$10bn) | 77.7% |
| Mid cap ($2-10bn) | 14.4% |
| Small cap (<$2bn) | 7.4% |
| Developed mkts. | 99.9% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 96.0 % |
 |
IRELAND | 2.5 % |
 |
NETHERLANDS | 1.5 % |
Historical Performance
Standardized Performance (as of 04/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -0.8% | 12.2% | 4.5% | 1.1% | -0.3% | 6.9% | -- | 9.6% |
| Dividend Yield | 0.2% | 1.0% | 0.7% | 0.5% | 0.4% | 0.2% | -- | 0.1% |
| Total Returns | -0.6% | 13.2% | 5.2% | 1.7% | 0.1% | 7.1% | -- | 9.7% | Ann. Volatility | 17.3% | 16.4% | 16.4% | 15.4% | 16.5% | 18.5% | -- | 19.1% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.81 | 37% |
| MSCI EAFE | 0.71 | 39% |
| MSCI Emg Mkts | 0.44 | 25% |
Liquidity Measures
| Avg. volume (000) | 17 |
| ADV traded (mns) | $2 |
| Turnover | 0.2% |
| Avg. Bid/Ask (% of price) | 0.27% |
Technical Indicators
| 30d moving avg. (EMA) | $112.03 |
| Relative strength (RSI) | 51 |
| MACD/Signal | 0.53/0.66 |
| Bollinger Bands (Upper/Lower) | $114.86/$110.73 |
| Short interest (% of AUM) | 0.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. FXH |
Expenses vs. FXH |
ALTAR Score™ vs. FXH |
|---|---|---|---|---|
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 53.7% | -22 bp | +1.7% |
| IYH | iShares U.S. Healthcare ETF | 37.8% | -22 bp | +1.0% |
| VHT | Vanguard Health Care ETF | 35.4% | -53 bp | +0.2% |
| FHLC | Fidelity MSCI Health Care Index ETF | 35.0% | -54 bp | +0.4% |
| XLV | Health Care Select Sector SPDR | 32.5% | -54 bp | +1.8% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 28.0% | -2 bp | +2.1% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 27.8% | +6 bp | -3.1% |
| IXJ | iShares Global Healthcare ETF | 27.8% | -20 bp | +1.5% |
| MDEV | First Trust Indxx Medical Devices ETF | 26.2% | +8 bp | 0.0% |
| XHS | State Street SPDR S&P Health Care Services ETF | 25.9% | -27 bp | -1.2% |
Risk and Returns: FXH vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/5/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
5.6%
ALTAR SCORE™
52nd
PERCENTILE
NEUTRAL
ETFRC RATING
There are 1,204 funds in the US Equity category with an average
ALTAR Score™ of 5.5% and a standard deviation
of 2.1%. FXH's ALTAR Score™ is approximately 0.1 standard
deviations above the category average. This places FXH in the 52nd percentile
among funds in the category.
Sell-Side Consensus
$138.09
PRICE TARGET
+22.7%
UPSIDE